## **Core Concept**
Lithium-induced diabetes insipidus (DI) is a condition characterized by polyuria due to the kidney's reduced ability to concentrate urine. This is often caused by lithium's effect on the kidneys' collecting ducts, making them less responsive to antidiuretic hormone (ADH), also known as vasopressin.

## **Why the Correct Answer is Right**
The treatment of choice for lithium-induced diabetes insipidus, which presents with polyuria, involves addressing the underlying issue of impaired renal response to ADH. **Amiloride** is a potassium-sparing diuretic that works by blocking epithelial sodium channels in the collecting ducts of the kidneys. It is specifically useful in treating lithium-induced nephrogenic diabetes insipidus because it can help reduce polyuria by enhancing the kidney's ability to concentrate urine.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not provided, but typically, incorrect options might include other diuretics or treatments not directly addressing the pathophysiology of lithium-induced DI.
- **Option B:** Similarly, not provided, but could involve medications that might worsen the condition or not directly treat the cause.
- **Option C:** This could potentially include other treatments for DI, such as **desmopressin**, which is more effective in central DI where there's a deficiency of ADH rather than a resistance to it.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **lithium-induced nephrogenic diabetes insipidus** is treated with **Amiloride** or sometimes **Thiazide diuretics** (paradoxically) to manage polyuria. Unlike central diabetes insipidus, where desmopressin (an ADH analogue) is the mainstay of treatment, nephrogenic DI requires a different approach due to the kidney's unresponsiveness to ADH.

## **Correct Answer:** . Amiloride